Drug Trial Radar · NCT07110246
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Nov 7, 2025
Primary completion
Mar 31, 2032
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rising Tide Foundation
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
Conditions
- BRAF V600 Mutation
- Low-grade Glioma
- Low Grade Glioma of Brain
- Recurrent Low Grade Glioma
Interventions
DabrafenibDrug
Given orally (PO)
TrametinibDrug
Given PO
Magnetic Resonance Imaging (MRI)Procedure
Undergo imaging by MRI
Specimen CollectionProcedure
Under collection of blood and optional CSF samples
Optional Lumbar punctureProcedure
Undergo optional lumbar puncture
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rebound rate (RR)Time frame: Up to a maximum of 34 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana · Recruiting
John Hopkins Medical Center
Baltimore, Maryland · Recruiting
St. Louis Children's Hospital Washington University in St. Louis
St Louis, Missouri · Recruiting
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.